688235 winning number

1. Recently, BeiGene (688235) and Stock Bar released new stock information. The subscription time for 688235 BeiGene is December 2, 2021, the subscription code is 787235, and the winning number of BeiGene is on December 5 Announced in the evening, the total number of shares issued was 115.05526 million shares, and the industry price-to-earnings ratio was 37.84. Friends who want to play new games in BeiGene, this article will continue to be updated, you can save it, and the lottery results will be updated on the evening of December 5th.

2. BeiGene online pricing issuance lottery results

The last "four" digits: 2069, 7069, 3951

The last "five" digits : 09207, 29207, 49207, 69207, 89207

The last "six" digits: 389763

The last "seven" digits: 2413241, 4413241, 6413241, 8413241, 0413241

3. Company Profile

BeiGene Co., Ltd. is a global, commercial-stage biotechnology company focusing on the research, development, production and commercialization of innovative drugs. Its main products are hundreds of Yueze ((BRUKINSA), BTK inhibitor), BrUKINSA (anti-PD-1 monoclonal antibody), pamiparib. The company's independently developed product BRUKINSA has achieved "zero breakthrough" in bringing China's original new drugs overseas. With this milestone breakthrough, it won the "Drug Innovation Award" issued by the China Health Industry Innovation Platform in 2020. In the same year, the company won the "2019 Zhangjiang Science City Outstanding Enterprise Innovation Achievement Award" issued by the Shanghai Zhangjiang Science City Construction and Management Office for its independently developed product Baizean. In addition, the company, as the undertaking unit, has conducted 5 national-level scientific research projects and published 34 academic papers in core journals. _

4. Business model

The company is a global biotechnology company covering the entire chain of early drug discovery, preclinical research, clinical trials, large-scale drug production and commercialization. Since its establishment 10 years ago, it has established a complete organizational structure and has independent and complete R&D, clinical, procurement, production, and sales systems.

1. The company’s main business model is as follows:

1. Research and development model

At the beginning of its establishment, the company developed its own platform for cancer biology and focused on research. The role and value of tumor-immune system interactions and primary tumor biopsies in developing new cancer models. At present, the company has established a variety of anti-tumor target and drug technology platforms. The R&D system covers molecular targeted drugs, immuno-oncology therapies, combination therapies, etc. The R&D engine can achieve seamless connection with production and clinical development.

2. The research and development process of the company’s innovative drugs includes the preclinical research stage, clinical trial stage, marketing application stage, product launch and post-marketing continuous research stage.

3. The company conducts preliminary target screening and antibody candidate evaluation based on its independently established core technology platform. Subsequently, the company conducts a comprehensive preclinical evaluation of the candidate drug molecules, including synthesis process, extraction method, dosage form selection, quality standards, stability, pharmacodynamics, pharmacokinetics, toxicology studies, etc. When a candidate drug has undergone sufficient preclinical comprehensive evaluation and proven effective and safe in animal or in vitro tests, the company will submit a new drug clinical research application for the candidate drug in accordance with the relevant provisions of the "Drug Registration Management Measures" and report the facts truthfully. Submit relevant information and samples such as development methods, quality indicators, pharmacological and toxicological test results.

4. After the new drug clinical research application is approved, the company will strictly follow the "Good Clinical Practice for Drugs" (GCP), "ICH GCP" and other relevant regulations to conduct clinical Phase I-Phase III trials. Phase I clinical trials are preliminary clinical pharmacology and human safety evaluation tests. The main purpose is to observe the human body's tolerance and pharmacokinetics of new drugs, and provide a basis for formulating dosage regimens and safe dosages.

5. Phase II clinical trials begin clinical research on patients to confirm the efficacy and safety of candidate drugs and obtain data on the effectiveness of drug treatment. Phase III clinical trials comprehensively examine the efficacy and safety of the candidate drug in patients, further obtain the effectiveness data of the candidate drug and identify side effects, as well as interactions with other drugs.

6. Clinical trial work is mainly undertaken by medical institutions that have the qualifications and necessary conditions for drug clinical trial institutions. As the trial sponsor, the company is responsible for providing treatment purposes and needs, clinical trial plans, experimental drugs, and working capital. . During the conduct of clinical trials, the company mainly uses its own clinical medicine and operations teams to supervise and manage clinical trials in accordance with international standards to ensure the standardization and data quality of clinical trials.

7. For some clinical trials, the company will entrust CROs such as PAREXEL, IQVIA, and Covance to provide some necessary R&D services, and in the process, it will conduct overall supervision of the trials through its own team. and management to ensure trial compliance and documentation of clinical data.